AHA: Baxdrostat Studied in Treatment-Resistant Hypertension

TUESDAY, Nov. 8, 2022 -- Patients with treatment-resistant hypertension who receive baxdrostat versus placebo have dose-dependent reductions in systolic blood pressure at 12 weeks, according to a study published online Nov. 7 in the New England...
Source: Drugs.com - Daily MedNews - Category: General Medicine Source Type: news